Carvedilol is a -adrenoreceptor–antagonist drug with 1-adrenoreceptor–antagonistactivity. It was approved in the United States in September1995 for the treatment of patients with essential hypertensionand in May 1997, on the basis of the results of several clinicaltrials,1,2,3,4,5,6,7,8 became the first adrenoreceptor-blockingdrug to receive approval for the treatment of symptomatic heartfailure.
Pharmacodynamic and Pharmacokinetic Properties
Carvedilol is a racemic lipophilic aryloxypropanolamine (Figure 1)that causes both precapillary vasodilatation by means of1-adrenoreceptor blockade and nonselective -adrenoreceptor blockadeand is devoid of intrinsic sympathomimetic activity.9 Its membrane-stabilizingactivity is less than that of propranolol. Milligram for milligram,carvedilol is . . . [Full Text of this Article]
Clinical Effectiveness
Congestive Heart Failure
Hypertension
Ischemic Heart Disease
Clinical Use in Heart Failure
Side Effects
Conclusions
Source Information
From the Departments of Medicine and Pharmacology, New York Medical College, Valhalla.
Address reprint requests to Dr. Frishman at the New York Medical College–Westchester Medical Center, Department of Medicine, Munger Pavilion, Valhalla, NY 10595.
References
Related Letters:
Carvedilol
Cohn L. J., Frishman W. H.
Extract |
Full Text
N Engl J Med 1999;
340:1443-1444, May 6, 1999.
Correspondence
This article has been cited by other articles:
Woodcock, E. A., Du, X.-J., Reichelt, M. E., Graham, R. M.
(2008). Cardiac {alpha}1-adrenergic drive in pathological remodelling. Cardiovasc Res
77: 452-462
[Abstract][Full Text]
Spallarossa, P., Altieri, P., Garibaldi, S., Ghigliotti, G., Barisione, C., Manca, V., Fabbi, P., Ballestrero, A., Brunelli, C., Barsotti, A.
(2006). Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res
69: 736-745
[Abstract][Full Text]
Samonakis, D N, Triantos, C K, Thalheimer, U, Patch, D W, Burroughs, A K
(2004). Management of portal hypertension. Postgrad. Med. J.
80: 634-641
[Abstract][Full Text]
Koshimizu, T.-a., Tsujimoto, G., Hirasawa, A., Kitagawa, Y., Tanoue, A.
(2004). Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human {alpha}1D- and {alpha}1B-adrenergic receptors. Cardiovasc Res
63: 662-672
[Abstract][Full Text]
Task Force Members, , Lopez-Sendo, J., Swedberg, K., McMurray, J., Tamargo, J., Maggioni, A. P., Dargie, H., Tendera, M., Waagstein, F., Kjekshus, J., Lechat, P., Pedersen, C. T., ESC Committee for Practice Guidelines, , Priori, S. G., Alonso Garcia, M. A., Blanc, J.-J., Budaj, A., Cowie, M., Dean, V., Deckers, J., Fernandez Burgos, E., Lekakis, J., Lindahl, B., Mazzotta, G., McGregor, K., Morais, J., Oto, A., Smiseth, O. A., Document Reviewers, , Alonso Garcia, M. A., Ardissino, D., Avendano, C., Lundqvist, C. B., ment, D. C., Drexler, H., Ferrari, R., Fox, K. A., Julian, D., Kearney, P., Klein, W., ber, L. K., Mancia, G., Nieminen, M., Ruzyllo, W., Simoons, M., Thygesen, K., Tognoni, G., Tritto, I., Wallentin, L.
(2004). Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J
25: 1341-1362
[Full Text]
Ohno, A., Saito, Y., Hanioka, N., Jinno, H., Saeki, M., Ando, M., Ozawa, S., Sawada, J.-i.
(2004). INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOL. Drug Metab. Dispos.
32: 235-239
[Abstract][Full Text]
Bollano, E, Tang, M S., Hjalmarson, A, Waagstein, F, Andersson, B
(2003). Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. Heart
89: 621-624
[Abstract][Full Text]
Taccetta-Chapnick, M.
(2002). Using Carvedilol to Treat Heart Failure. Crit Care Nurse
22: 36-58
[Full Text]
Frishman, W. H.
(2001). Update in Cardiology. ANN INTERN MED
135: 439-446
[Full Text]
Gomberg-Maitland, M., Baran, D. A., Fuster, V.
(2001). Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist. Arch Intern Med
161: 342-352
[Abstract][Full Text]
Mortara, A., La Rovere, M. T., Pinna, G. D., Maestri, R., Capomolla, S., Cobelli, F.
(2000). Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol
36: 1612-1618
[Abstract][Full Text]
Wei, S., Chow, L. T. C., Sanderson, J. E.
(2000). Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol
36: 276-281
[Abstract][Full Text]
Pearson, G. D., Veille, J.-C., Rahimtoola, S., Hsia, J., Oakley, C. M., Hosenpud, J. D., Ansari, A., Baughman, K. L.
(2000). Peripartum Cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) Workshop Recommendations and Review. JAMA
283: 1183-1188
[Abstract][Full Text]
Sanderson, J. E., Chan, S. K. W., Yip, G., Yeung, L. Y. C., Chan, K. W., Raymond, K., Woo, K. S.
(1999). Beta-blockade in heart failure: A comparison of carvedilol with metoprolol. J Am Coll Cardiol
34: 1522-1528
[Abstract][Full Text]
Davies, C.H., Bashir, Y.
(1999). Beta-blockers for heart failure-time to think the unthinkable?. QJM
92: 673-678
[Full Text]
Crysant, S. G.
(1999). Carvedilol. Arch Fam Med
8: 295-295
[Full Text]
Cohn, L. J., Frishman, W. H.
(1999). Carvedilol. NEJM
340: 1443-1444
[Full Text]
-adrenoreceptor–antagonist drug with 
1-adrenoreceptor–antagonist activity. It was approved in the United States in September 1995 for the treatment of patients with essential hypertension and in May 1997, on the basis of the results of several clinical trials,1,2,3,4,5,6,7,8 became the first adrenoreceptor-blocking drug to receive approval for the treatment of symptomatic heart failure. 
Previous
